Ken Griffin Esperion Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.61 - $2.73 $34,776 - $58,968	-21,600 Reduced 5.52%	369,400 $609,000
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $281,520 - $495,720	153,000 Added 64.29%	391,000 $868,000
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $199,576 - $298,376	98,800 Added 70.98%	238,000 $637,000
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $62,926 - $265,496	86,200 Added 162.64%	139,200 $416,000
Q3 2023 Nov 14, 2023	SELL	$0.96 - $1.79 $76,704 - $143,021	-79,900 Reduced 60.12%	53,000 $51,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $59,520 - $87,296	-49,600 Reduced 27.18%	132,900 $184,000
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $64,824 - $324,120	-44,400 Reduced 19.57%	182,500 $290,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $863,773 - $1.44 Million	169,700 Added 296.68%	226,900 $1.41 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $103,550 - $154,470	19,000 Added 49.74%	57,200 $383,000

208

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.